{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:15:12Z","timestamp":1784304912100,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["800983"],"award-info":[{"award-number":["800983"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022011","name":"CRUK","doi-asserted-by":"publisher","award":["C18281\/A29019"],"award-info":[{"award-number":["C18281\/A29019"]}],"id":[{"id":"10.13039\/501100022011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/L016494\/1"],"award-info":[{"award-number":["EP\/L016494\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.toxicon.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T11:16:21Z","timestamp":1655291781000},"page":"77-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Developing a computational pharmacokinetic model of systemic snakebite envenomation and antivenom treatment"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-5832","authenticated-orcid":false,"given":"Natalie M.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna A.","family":"Blee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-7306","authenticated-orcid":false,"given":"Sabine","family":"Hauert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2022.06.006_bib1","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/toxins6082541","article-title":"Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential","volume":"6","author":"Alvarenga","year":"2014","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.toxicon.2022.06.006_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/taap.1997.8363","article-title":"Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab\u2019)2","volume":"150","author":"Bazin-Redureau","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/15563650.2020.1726377","article-title":"Snake bites by European vipers in Mainland France in 2017-2018: comparison of two antivenoms Viperfav\u00ae and Viperatab\u00ae","volume":"58","author":"Boels","year":"2020","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics","volume":"10","author":"Boxenbaum","year":"1982","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.toxicon.2022.06.006_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/archinte.159.7.706","article-title":"Recurrent and persistent coagulopathy following pit viper envenomation","volume":"159","author":"Boyer","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.toxicon.2022.06.006_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1208\/s12248-012-9369-y","article-title":"Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics","volume":"14","author":"Bumbaca","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.toxicon.2022.06.006_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/15563650.2014.974263","article-title":"Comparison of F(ab\u2019)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial","volume":"53","author":"Bush","year":"2015","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0041-0101(98)00216-5","article-title":"Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2","volume":"37","author":"Calder\u00f3n-Aranda","year":"1999","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2460\/javma.259.5.503","article-title":"Retrospective comparison of three antivenoms for the treatment of dogs with crotalid envenomation","volume":"259","author":"Carotenuto","year":"2021","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.toxicon.2022.06.006_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2020.05.006","article-title":"Causes and consequences of snake venom variation","volume":"41","author":"Casewell","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.toxicon.2022.06.006_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/247645","article-title":"Cross-Reactivity against Naja sumatrana (black spitting cobra) envenoming from the haffkine antivenom in a mouse model","author":"Cham","year":"2013","journal-title":"ISRN Toxicol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/intimm\/dxu082","article-title":"The role of phage display in therapeutic antibody discovery","volume":"26","author":"Chan","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib14","doi-asserted-by":"crossref","first-page":"E104","DOI":"10.3390\/toxins11020104","article-title":"Exploring the diversity and novelty of toxin genes in Naja sumatrana, the equatorial spitting cobra from Malaysia through de Novo venom-Gland transcriptomics","volume":"11","author":"Chong","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1067\/mem.2001.113372","article-title":"Efficacy, safety, and use of snake antivenoms in the United States","volume":"37","author":"Dart","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2022.06.006_bib16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1124\/dmd.119.086488","article-title":"Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides","volume":"47","author":"Datta-Mannan","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxicon.2022.06.006_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bcp.12739","article-title":"Adverse reactions to snake antivenom, and their prevention and treatment","volume":"81","author":"de Silva","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ki.1979.138","article-title":"Macromolecule transport across glomerular capillaries: application of pore theory","volume":"16","author":"Deen","year":"1979","journal-title":"Kidney Int."},{"key":"10.1016\/j.toxicon.2022.06.006_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0041-0101(02)00178-2","article-title":"Intraspecific variability and pharmacokinetic characteristics of Androctonus mauretanicus mauretanicus scorpion venom","volume":"40","author":"El Hafny","year":"2002","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00002018-200427140-00004","article-title":"Fab antibody fragments: some applications in clinical toxicology","volume":"27","author":"Flanagan","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.toxicon.2022.06.006_bib21","first-page":"1","article-title":"Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab\u2019)2 to Fab antivenom","author":"Gerardo","year":"2021","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib22","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.toxicon.2022.06.006_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00003088-200342080-00002","article-title":"Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation","volume":"42","author":"Guti\u00e9rrez","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxicon.2022.06.006_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.toxicon.2022.06.006_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.biopha.2017.04.039","article-title":"Effect of premedication with subcutaneous adrenaline on the pharmacokinetics and immunogenicity of equine whole IgG antivenom in a rabbit model","volume":"90","author":"Herrera","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.toxicon.2022.06.006_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.toxicon.2022.06.006_bib28","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1074\/jbc.M111.311522","article-title":"Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains *","volume":"287","author":"Hutt","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxicon.2022.06.006_bib29","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0041-0101(98)00144-5","article-title":"Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use","volume":"36","author":"Ismail","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0041-0101(97)00062-7","article-title":"Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its specific antivenins: flash absorption and distribution of the venom and its toxin versus slow absorption and distribution of IgG, F(ab')2 and F(ab) of the antivenin","volume":"36","author":"Ismail","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0041-0101(96)00055-4","article-title":"A three-compartment open pharmacokinetic model can explain variable toxicities of cobra venoms and their alpha toxins","volume":"34","author":"Ismail","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/toxins11010053","article-title":"Toxin neutralization using alternative binding proteins","volume":"11","author":"Jenkins","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00703","article-title":"Cost of manufacturing for recombinant snakebite antivenoms","volume":"8","author":"Jenkins","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib34","series-title":"Antibody Methods and Protocols, Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-61779-931-0_15","article-title":"PEGylation of antibody fragments for half-life extension","author":"Jev\u0161evar","year":"2012"},{"key":"10.1016\/j.toxicon.2022.06.006_bib35","series-title":"Comprehensive Toxicology","first-page":"153","article-title":"1.08 - modeling of disposition","author":"Johanson","year":"2010"},{"key":"10.1016\/j.toxicon.2022.06.006_bib36","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.toxicon.2010.07.010","article-title":"Structure, function and evolution of three-finger toxins: mini proteins with multiple targets","volume":"56","author":"Kini","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3390\/toxins10120534","article-title":"Biosynthetic oligoclonal antivenom (BOA) for snakebite and next-generation treatments for snakebite victims","volume":"10","author":"Kini","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib38","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1016\/S0021-9258(18)68146-3","article-title":"Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers","volume":"263","author":"Knauf","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxicon.2022.06.006_bib39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0041-0101(01)00083-6","article-title":"Effects of antivenom on Buthus occitanus tunetanus (Bot) scorpion venom pharmacokinetics: towards an optimization of antivenom immunotherapy in a rabbit model","volume":"39","author":"Krifi","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.toxicon.2004.10.007","article-title":"Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy","volume":"45","author":"Krifi","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib41","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.3390\/cancers13184620","article-title":"Improving biologics' effectiveness in clinical oncology: from the combination of two monoclonal antibodies to oligoclonal antibody mixtures","volume":"13","author":"Larbouret","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.toxicon.2022.06.006_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15569543.2016.1220397","article-title":"Toxin synergism in snake venoms","volume":"35","author":"Laustsen","year":"2016","journal-title":"Toxin Rev."},{"key":"10.1016\/j.toxicon.2022.06.006_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005361","article-title":"Recombinant snakebite antivenoms: a cost-competitive solution to a neglected tropical disease?","volume":"11","author":"Laustsen","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.toxicon.2022.06.006_bib44","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1038\/s41467-018-06086-4","article-title":"In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies","volume":"9","author":"Laustsen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxicon.2022.06.006_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxicon.2018.03.004","article-title":"Pros and cons of different therapeutic antibody formats for recombinant antivenom development","volume":"146","author":"Laustsen","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib46","series-title":"In Vitro Discovery and Optimization of a Human Monoclonal Antibody that Neutralizes Neurotoxicity and Lethality of Cobra Snake Venom","author":"Ledsgaard","year":"2021"},{"key":"10.1016\/j.toxicon.2022.06.006_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0041-0101(00)00209-9","article-title":"Comparison between IgG and F(ab')2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions","volume":"39","author":"Le\u00f3n","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxicon.2018.06.084","article-title":"Current technology for the industrial manufacture of snake antivenoms","volume":"151","author":"Le\u00f3n","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actatropica.2015.05.020","article-title":"Immunological cross-reactivity and neutralization of the principal toxins of Naja sumatrana and related cobra venoms by a Thai polyvalent antivenom (Neuro Polyvalent Snake Antivenom)","volume":"149","author":"Leong","year":"2015","journal-title":"Acta Trop."},{"key":"10.1016\/j.toxicon.2022.06.006_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/BJ20060004","article-title":"Novel genes encoding six kinds of three-finger toxins in Ophiophagus hannah (king cobra) and function characterization of two recombinant long-chain neurotoxins","volume":"398","author":"Li","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.toxicon.2022.06.006_bib51","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s11095-017-2219-y","article-title":"Influence of molecular size on the clearance of antibody fragments","volume":"34","author":"Li","year":"2017","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.toxicon.2022.06.006_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","article-title":"Influence of molecular size on tissue distribution of antibody fragments","volume":"8","author":"Li","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2022.06.006_bib53","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/dmd.119.087809","article-title":"Effect of size on solid tumor disposition of protein therapeutics","volume":"47","author":"Li","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxicon.2022.06.006_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","article-title":"Two-pore physiologically based pharmacokinetic model with de Novo derived parameters for predicting plasma PK of different size protein therapeutics","volume":"46","author":"Li","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.toxicon.2022.06.006_bib55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.112.191999","article-title":"A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition","volume":"341","author":"Luu","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.toxicon.2022.06.006_bib56","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.toxicon.2022.06.006_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.toxicon.2020.08.002","article-title":"Comparison of F(ab\u2019)2 and Fab antivenoms in rattlesnake envenomation: first year's post-marketing experience with F(ab\u2019)2 in New Mexico","volume":"186","author":"Mascarenas","year":"2020","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib58","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0041-0101(94)90341-7","article-title":"Snake antivenoms from hyperimmunized horses: comparison of the antivenom activity and biological properties of their whole IgG and F(ab\u2019)2 fragments","volume":"32","author":"Morais","year":"1994","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib59","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1248\/bpb.b19-01042","article-title":"Predicting method for the human plasma concentration-time profile of a monoclonal antibody from the half-life of non-human primates","volume":"43","author":"Nakamura","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.toxicon.2022.06.006_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2016.06.018","article-title":"Development of a chicken-derived antivenom against the taipan snake (Oxyuranus scutellatus) venom and comparison with an equine antivenom","volume":"120","author":"Navarro","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib61","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxcx.2020.100052","article-title":"Snake venom metalloproteinases (SVMPs): a structure-function update","volume":"7","author":"Olaoba","year":"2020","journal-title":"Toxicon X"},{"key":"10.1016\/j.toxicon.2022.06.006_bib63","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0041-008X(96)80033-0","article-title":"Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions","volume":"141","author":"P\u00e9pin-Covatta","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.toxicon.2006.05.010","article-title":"Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits","volume":"48","author":"Quesada","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib65","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3389\/fimmu.2021.668328","article-title":"A quest for a universal plasma-derived antivenom against all elapid neurotoxic snake venoms","volume":"12","author":"Ratanabanangkoon","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib66","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.toxicon.2004.10.019","article-title":"Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms","volume":"45","author":"Raweerith","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib67","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1152\/japplphysiol.00389.2006","article-title":"A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles","volume":"101","author":"Reddy","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069495","article-title":"In vivo neutralization of \u03b1-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody","volume":"8","author":"Richard","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.toxicon.2022.06.006_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)36597-8","article-title":"Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy","volume":"281","author":"Rivi\u00e8re","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.toxicon.2022.06.006_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2013.03.013","article-title":"Role of the animal model on the pharmacokinetics of equine-derived antivenoms","volume":"70","author":"Rojas","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.toxicon.2014.11.001","article-title":"Phage display as a novel promising antivenom therapy: a review","volume":"93","author":"Roncolato","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib72","series-title":"Clinical Pharmacokinetics Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.toxicon.2022.06.006_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.toxicon.2022.06.006_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10020073","article-title":"Pharmacokinetics of snake venom","volume":"10","author":"Sanhajariya","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/toxins12030188","article-title":"The influence of the different disposition characteristics of snake toxins on the pharmacokinetics of snake venom","volume":"12","author":"Sanhajariya","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib76","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.bioconjchem.6b00469","article-title":"Approach for half-life extension of small antibody fragments that does not affect tissue uptake","volume":"27","author":"Schneider","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.toxicon.2022.06.006_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mem.2001.113135","article-title":"Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies","volume":"37","author":"Seifert","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.toxicon.2022.06.006_bib78","first-page":"19","article-title":"The long road of research on snake venom serine proteinases","volume":"62","author":"Serrano","year":"2013","journal-title":"Toxicon, Milest. Future Prospects Snake Venom Res."},{"key":"10.1016\/j.toxicon.2022.06.006_bib79","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.toxicon.2004.07.032","article-title":"Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab\u2019)2 extrusion mechanism from blood to tissues","volume":"44","author":"Sevcik","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","article-title":"Antibody biodistribution coefficients","volume":"5","author":"Shah","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2022.06.006_bib81","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.intimp.2013.10.007","article-title":"Pharmacokinetics of Cryptelytrops purpureomaculatus (mangrove pit viper) venom following intravenous and intramuscular injections in rabbits","volume":"17","author":"Sim","year":"2013","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.toxicon.2022.06.006_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(00)00105-0","article-title":"The expanding superfamily of phospholipase A2 enzymes: classification and characterization","volume":"1488","author":"Six","year":"2000","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.toxicon.2022.06.006_bib83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.copbio.2007.04.010","article-title":"Alternative non-antibody scaffolds for molecular recognition","volume":"18","author":"Skerra","year":"2007","journal-title":"Curr. Opin. Biotechnol. Protein Technol.\/Syst. Biol."},{"key":"10.1016\/j.toxicon.2022.06.006_bib84","first-page":"1","article-title":"In silico modelling of cancer nanomedicine, across scales and transport barriers","volume":"6","author":"Stillman","year":"2020","journal-title":"npj Computat. Mater."},{"key":"10.1016\/j.toxicon.2022.06.006_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/srep37299","article-title":"Assessing SABU (Serum Anti Bisa Ular), the sole Indonesian antivenom: a proteomic analysis and neutralization efficacy study","volume":"6","author":"Tan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxicon.2022.06.006_bib86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/toxins8040086","article-title":"Neutralization of the principal toxins from the venoms of Thai Naja kaouthia and Malaysian hydrophis schistosus: insights into toxin-specific neutralization by two different antivenoms","volume":"8","author":"Tan","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9090290","article-title":"A review and database of snake venom proteomes","volume":"9","author":"Tasoulis","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2022.06.006_bib88","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1096\/fj.201903231R","article-title":"Serum albumin-binding VHHs with variable pH sensitivities enable tailored half-life extension of biologics","volume":"34","author":"van Faassen","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.toxicon.2022.06.006_bib89","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.toxicon.2013.09.004","article-title":"Production of anti-horse antibodies induced by IgG, F(ab\u2019)2 and Fab applied repeatedly to rabbits. Effect on antivenom pharmacokinetics","volume":"76","author":"V\u00e1zquez","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib90","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.intimp.2010.01.005","article-title":"Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab\u2019)2, IgG and IgG(T) fragments from hyper immune equine plasma","volume":"10","author":"V\u00e1zquez","year":"2010","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.toxicon.2022.06.006_bib91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bdd.1952","article-title":"Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development","volume":"37","author":"Wang","year":"2016","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.toxicon.2022.06.006_bib92","series-title":"Initial Experience with F(ab\u2019)2 Antivenom Compared with Fab Antivenom for Rattlesnake Envenomations Reported to a Single Poison Center during 2019","author":"Wilson","year":"2022"},{"key":"10.1016\/j.toxicon.2022.06.006_bib93","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s11095-012-0708-6","article-title":"Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence","volume":"29","author":"Wu","year":"2012","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.toxicon.2022.06.006_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.actatropica.2014.01.014","article-title":"Proteomic characterization of venom of the medically important Southeast Asian Naja sumatrana (Equatorial spitting cobra)","volume":"133","author":"Yap","year":"2014","journal-title":"Acta Trop."},{"key":"10.1016\/j.toxicon.2022.06.006_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.toxicon.2013.02.017","article-title":"Toxicokinetics of Naja sputatrix (Javan spitting cobra) venom following intramuscular and intravenous administrations of the venom into rabbits","volume":"68","author":"Yap","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2022.06.006_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002890","article-title":"Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits","volume":"8","author":"Yap","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.toxicon.2022.06.006_bib97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jps.21089","article-title":"On the volume of distribution at steady state and its relationship with two-compartmental models","volume":"97","author":"Yates","year":"2008","journal-title":"J. Pharmaceut. Sci."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010122001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010122001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:21:25Z","timestamp":1758576085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010122001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":96,"alternative-id":["S0041010122001891"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2022.06.006","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a computational pharmacokinetic model of systemic snakebite envenomation and antivenom treatment","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}